NEW YORK (GenomeWeb News) — Gene Bridges will use its recombination technology in collaboration with BASF in a genetic-engineering project using E. coli, Gene Bridges said Wednesday.
 
Under the agreement, Heidelberg, Germany-based Gene Bridges will use its Red/ET technology in bio-molecular engineering tasks, and BASF will perform screening and product and process development projects.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.